Free Trial

Tokio Marine Asset Management Co. Ltd. Has $12.16 Million Position in Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logo with Medical background

Key Points

  • Tokio Marine Asset Management Co. Ltd. increased its holdings in Johnson & Johnson by 7.0%, owning 73,350 shares valued at approximately $12.16 million as per its recent SEC filing.
  • Johnson & Johnson's stock is currently down 0.6%, with a market capitalization of $416.14 billion and has shown a revenue increase of 5.8% year-over-year.
  • The company has announced a quarterly dividend of $1.30 per share, representing a yield of 3.0%, set to be paid on September 9th to investors of record as of August 26th.
  • Looking to export and analyze Johnson & Johnson data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Tokio Marine Asset Management Co. Ltd. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 7.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 73,350 shares of the company's stock after buying an additional 4,816 shares during the quarter. Tokio Marine Asset Management Co. Ltd.'s holdings in Johnson & Johnson were worth $12,164,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Elios Financial Group Inc. grew its stake in Johnson & Johnson by 1.5% in the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock valued at $746,000 after purchasing an additional 66 shares in the last quarter. Atlantic Family Wealth LLC lifted its position in shares of Johnson & Johnson by 4.4% in the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after buying an additional 67 shares during the last quarter. MBA Advisors LLC lifted its position in shares of Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after buying an additional 68 shares during the last quarter. Sovereign Financial Group Inc. lifted its position in shares of Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after buying an additional 69 shares during the last quarter. Finally, Nabity Jensen Investment Management Inc lifted its position in shares of Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after buying an additional 69 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on JNJ. Barclays raised their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Royal Bank Of Canada lifted their price target on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Morgan Stanley lifted their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Finally, Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Nine analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $174.50.

View Our Latest Research Report on Johnson & Johnson

Johnson & Johnson Price Performance

JNJ stock traded up $2.04 during midday trading on Friday, reaching $176.76. 9,470,267 shares of the stock were exchanged, compared to its average volume of 9,042,142. The stock has a market capitalization of $425.70 billion, a PE ratio of 18.90, a P/E/G ratio of 2.22 and a beta of 0.41. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $177.27. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a fifty day moving average price of $160.85 and a 200 day moving average price of $158.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. Johnson & Johnson's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.82 EPS. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson's payout ratio is currently 55.61%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Stocks With Explosive Upside
September Slowdown: 3 Stocks to Buy When the Pullback Comes
3 Overlooked Stocks Riding the AI Data Center Boom

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines